Switch theme
Sign up to access all valuation multiples
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
2009
286
LTM Revenue $58.8M
LTM EBITDA -$218M
$287M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nurix Therapeutics has a last 12-month revenue (LTM) of $58.8M and a last 12-month EBITDA of -$218M.
In the most recent fiscal year, Nurix Therapeutics achieved revenue of $54.5M and an EBITDA of -$197M.
Nurix Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nurix Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $58.8M | XXX | $54.5M | XXX | XXX | XXX |
| Gross Profit | $58.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$218M | XXX | -$197M | XXX | XXX | XXX |
| EBITDA Margin | -371% | XXX | -360% | XXX | XXX | XXX |
| EBIT | -$246M | XXX | -$213M | XXX | XXX | XXX |
| EBIT Margin | -418% | XXX | -391% | XXX | XXX | XXX |
| Net Profit | -$226M | XXX | -$194M | XXX | XXX | XXX |
| Net Margin | -385% | XXX | -355% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nurix Therapeutics's stock price is $11.
Nurix Therapeutics has current market cap of $810M, and EV of $287M.
See Nurix Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $287M | $810M | XXX | XXX | XXX | XXX | $-2.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nurix Therapeutics has market cap of $810M and EV of $287M.
Nurix Therapeutics's trades at 5.2x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Nurix Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nurix Therapeutics has a P/E ratio of -3.6x.
See valuation multiples for Nurix Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $810M | XXX | $810M | XXX | XXX | XXX |
| EV (current) | $287M | XXX | $287M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.6x | XXX | -4.1x | XXX | XXX | XXX |
| EV/FCF | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNurix Therapeutics's last 12 month revenue growth is 10%
Nurix Therapeutics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Nurix Therapeutics's rule of 40 is -185% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nurix Therapeutics's rule of X is -347% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nurix Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | -371% | XXX | -363% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -185% | XXX | -353% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -347% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 406% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 491% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nurix Therapeutics acquired XXX companies to date.
Last acquisition by Nurix Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Nurix Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nurix Therapeutics founded? | Nurix Therapeutics was founded in 2009. |
| Where is Nurix Therapeutics headquartered? | Nurix Therapeutics is headquartered in United States of America. |
| How many employees does Nurix Therapeutics have? | As of today, Nurix Therapeutics has 286 employees. |
| Who is the CEO of Nurix Therapeutics? | Nurix Therapeutics's CEO is Dr. Arthur T. Sands, M.D.,PhD. |
| Is Nurix Therapeutics publicy listed? | Yes, Nurix Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Nurix Therapeutics? | Nurix Therapeutics trades under NRIX ticker. |
| When did Nurix Therapeutics go public? | Nurix Therapeutics went public in 2020. |
| Who are competitors of Nurix Therapeutics? | Similar companies to Nurix Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nurix Therapeutics? | Nurix Therapeutics's current market cap is $810M |
| What is the current revenue of Nurix Therapeutics? | Nurix Therapeutics's last 12 months revenue is $58.8M. |
| What is the current revenue growth of Nurix Therapeutics? | Nurix Therapeutics revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Nurix Therapeutics? | Current revenue multiple of Nurix Therapeutics is 4.9x. |
| Is Nurix Therapeutics profitable? | Yes, Nurix Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nurix Therapeutics? | Nurix Therapeutics's last 12 months EBITDA is -$218M. |
| What is Nurix Therapeutics's EBITDA margin? | Nurix Therapeutics's last 12 months EBITDA margin is -371%. |
| What is the current EV/EBITDA multiple of Nurix Therapeutics? | Current EBITDA multiple of Nurix Therapeutics is -1.3x. |
| What is the current FCF of Nurix Therapeutics? | Nurix Therapeutics's last 12 months FCF is -$176M. |
| What is Nurix Therapeutics's FCF margin? | Nurix Therapeutics's last 12 months FCF margin is -298%. |
| What is the current EV/FCF multiple of Nurix Therapeutics? | Current FCF multiple of Nurix Therapeutics is -1.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
